Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.

[1]  O. Merimsky,et al.  Combining an EGFR directed tyrosine kinase inhibitor with autophagy-inducing drugs: a beneficial strategy to combat non-small cell lung cancer. , 2011, Cancer letters.

[2]  X. Hao,et al.  Fangchinoline induces autophagic cell death via p53/sestrin2/AMPK signalling in human hepatocellular carcinoma cells , 2011, British journal of pharmacology.

[3]  E. Morselli,et al.  p53 inhibits autophagy by interacting with the human ortholog of yeast Atg17, RB1CC1/FIP200 , 2011, Cell cycle.

[4]  Xiaoying Lin,et al.  EGFR Tyrosine Kinase Inhibitors Activate Autophagy as a Cytoprotective Response in Human Lung Cancer Cells , 2011, PloS one.

[5]  S. Ghavami,et al.  Mevalonate Cascade Regulation of Airway Mesenchymal Cell Autophagy and Apoptosis: A Dual Role for p53 , 2011, PloS one.

[6]  Z. Fan,et al.  Roles of autophagy in cetuximab-mediated cancer therapy against EGFR , 2010, Autophagy.

[7]  Z. Fan,et al.  The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex. , 2010, Cancer research.

[8]  N. Tanner,et al.  Lung cancer: Progress in diagnosis, staging and therapy , 2010, Respirology.

[9]  M. Boulton,et al.  Using LC3 to monitor autophagy flux in the retinal pigment epithelium , 2009, Autophagy.

[10]  R. Salgia,et al.  The role of EGFR inhibition in the treatment of non-small cell lung cancer. , 2009, The oncologist.

[11]  E. Morselli,et al.  Stimulation of autophagy by the p53 target gene Sestrin2 , 2009, Cell cycle.

[12]  M. Dyer,et al.  Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. , 2009, The Journal of clinical investigation.

[13]  Baoxiang Zhao,et al.  Protective effects of a synthesized butyrolactone derivative against chloroquine-induced autophagic vesicle accumulation and the disturbance of mitochondrial membrane potential and Na+,K+-ATPase activity in vascular endothelial cells. , 2009, Chemical research in toxicology.

[14]  D. Stolz,et al.  Involvement of Protective Autophagy in TRAIL Resistance of Apoptosis-defective Tumor Cells* , 2008, Journal of Biological Chemistry.

[15]  A. Apel,et al.  Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. , 2008, Cancer research.

[16]  F. Inagaki,et al.  The Atg12-Atg5 Conjugate Has a Novel E3-like Activity for Protein Lipidation in Autophagy* , 2007, Journal of Biological Chemistry.

[17]  A. Gazdar,et al.  Lung cancer in never smokers — a different disease , 2007, Nature Reviews Cancer.

[18]  N. Mizushima,et al.  How to Interpret LC3 Immunoblotting , 2007, Autophagy.

[19]  J. Duyster,et al.  The anticancer drug imatinib induces cellular autophagy , 2007, Leukemia.

[20]  E. Henson,et al.  Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy. , 2006, Cellular signalling.

[21]  M. Tsuboi,et al.  Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib , 2006, Clinical Cancer Research.

[22]  M. Meyerson,et al.  Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[23]  M. Hall,et al.  TOR Signaling in Growth and Metabolism , 2006, Cell.

[24]  G. Silvestri,et al.  One hundred years of lung cancer. , 2005, American journal of respiratory and critical care medicine.

[25]  Eric H. Baehrecke,et al.  Autophagy: dual roles in life and death? , 2005, Nature Reviews Molecular Cell Biology.

[26]  Patricia L. Harris,et al.  Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[27]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[28]  R. Herbst,et al.  Targeting the epidermal growth factor receptor in non-small cell lung cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  Chan Zeng,et al.  Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  I. Germano,et al.  Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. , 2003, Cancer research.

[31]  P. Bunn,et al.  Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. , 2002, Seminars in oncology.

[32]  John Mendelsohn,et al.  The EGF receptor family as targets for cancer therapy , 2000, Oncogene.

[33]  S. Emr,et al.  Autophagy as a regulated pathway of cellular degradation. , 2000, Science.

[34]  S. Moro,et al.  MG-2477, a new tubulin inhibitor, induces autophagy through inhibition of the Akt/mTOR pathway and delayed apoptosis in A549 cells. , 2012, Biochemical pharmacology.

[35]  G. Bjørkøy,et al.  Monitoring autophagic degradation of p62/SQSTM1. , 2009, Methods in enzymology.

[36]  高坂 貴行.  Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib , 2007 .